Expression of LncRNA-MALAT1 in Type 2 Diabetic Patients with or without Coronary Artery Disease

Sadia Arif, Fouzia Shaikh, Shumaila Usman, Najia Tabassum, Faisal Memon, Aliya Irshad Sani


The development of type-2 diabetes mellitus (T2DM) has been linked to environmental, genetic, and epigenetic risk factors. Long non-coding RNAs (lncRNAs) play a role in the pathophysiology of complicated disorders and can also be used as diagnostic indicators. The literature strongly supports the implication of these lncRNAs in certain metabolic disorders. In this regard, one of the lncRNAs Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) expressions is also under investigation concerning diabetes and its related complications. There are few researches on the relationship between T2DM progression and MALAT1 dysregulation, and this study was undertaken to investigate this link further and gain a better knowledge of its clinical significance in the diagnosis and prognosis of T2DM. Therefore, the purpose of this study was to assess the gene expression of lncRNA MALAT1 in healthy controls, type 2 diabetics, and T2DM patients with the presence of coronary artery disease complications. This study was the case-control one performed on blood samples followed by centrifugation to separate the buffy coat. Then total RNA was extracted from buffy coat using triazole method followed by quantifying its expression levels by quantitative polymerase chain reaction (qPCR). The results of our study showed the significant up-regulation of lncRNAs-MALAT1 expression in patients with T2DM 1.22 (3.7) and T2DM with related coronary artery disease (CAD) complications 1.95 (2.10) (p-value <0.001). These findings suggest that modulating the expression of lncRNA MALAT1 may be a future strategy for diagnosing and treating diabetes-related complications like CAD.


Keywords: long non-coding RNAs, metastasis associated lung adenocarcinoma transcript 1, quantitative polymerase chain reaction. 

Full Text:



OGURTSOVA K., DA FERNANDES R.J, HUANG Y., LINNENKAMP U, GUARIGUATA L., CHO N.H., CAVAN D., SHAW J.E., and MAKAROFF L.E. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Research and Clinical Practice, 2017, 128: 40-50.

SAEEDI P., SALPEA P., KARURANGA S., PETERSOHN I., MALANDA B., GREGG E.W., UNWIN N., WILD S.H., and WILLIAMS R. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice, 2020, 162: 108086.

CHAWLA A., CHAWLA R., and JAGGI S. Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? Indian journal of endocrinology and metabolism. 2016, 20(4): 546.

STRISCIUGLIO T., IZZO R., BARBATO E., DI GIOIA G., COLAIORI I., FIORDELISI A., MORISCO C., BARTUNEK J., FRANCO D., AMMIRATI G., PERGOLA V., IMPARATO L., TRIMARCO B., ESPOSITO G., and RAPACCIUOLO A. Insulin resistance predicts severity of coronary atherosclerotic disease in non-diabetic patients. Journal of Clinical Medicine, 2020, 9(7): 2144.

RAJBHANDARI J., FERNANDEZ C.J., AGARWAL M., YEAP B.X.Y., and PAPPACHAN J.M. Diabetic heart disease: A clinical update. World Journal of Diabetes, 2021, 12(4): 383.

ABDULLE L.E., HAO J.-L., PANT O.P., LIU X.-F., ZHOU D.-D., GAO Y., SUWAL A., and LU C.-W. MALAT1 as a Diagnostic and Therapeutic Target in Diabetes-Related Complications: A Promising Long-Noncoding RNA. International Journal of Medical Sciences, 2019, 16(4): 548.

WANG C., WANG L., DING Y., LU X., ZHANG G., YANG J., ZHENG H., WANG H., JIANG Y., and XU L. LncRNA structural characteristics in epigenetic regulation. International Journal of Molecular Sciences, 2017, 18(12): 2659.

WANG G., LI Y., PENG Y., TANG J., and LI H. Association of polymorphisms in MALAT1 with risk of coronary atherosclerotic heart disease in a Chinese population. Lipids in Health and Disease, 2018, 17(1): 75.

TELLO-FLORES V.A., VALLADARES-SALGADO A., RAMÍREZ-VARGAS M.A., CRUZ M., DEL-MORAL-HERNÁNDEZ O., CAHUA-PABLO J.Á., RAMÍREZ M., HERNÁNDEZ-SOTELO D., ARMENTA-SOLIS A., and FLORES-ALFARO E. Altered levels of MALAT1 and H19 derived from serum or serum exosomes associated with type-2 diabetes. Non-coding RNA Research, 2020, 5(2): 71-6.

TANG N., JIANG S., YANG Y., LIU S., PONNUSAMY M., XIN H., and YU T. Noncoding RNAs as therapeutic targets in atherosclerosis with diabetes mellitus. Cardiovascular therapeutics, 2018, 36(4): e12436.

WONG W.K., JIANG G., SØRENSEN A.E., CHEW Y.V., LEE-MAYNARD C., LIUWANTARA D., WILLIAMS L., O'CONNELL P.J., DALGAARD L.T., MA R.C., HAWTHORNE W.J., JOGLEKAR M.V., and HARDIKAR A.A. The long non-coding RNA MALAT1 predicts human islet isolation quality. JCI Insight, 2019, 4(16).

LOTFY M., ADEGHATE J., KALASZ H., SINGH J., and ADEGHATE E. Chronic complications of diabetes mellitus: a mini-review. Current diabetes reviews, 2017, 13(1): 3-10.

HIMANSHU D., ALI W., and WAMIQUE M. Type 2 diabetes mellitus: pathogenesis and genetic diagnosis. Journal of Diabetes & Metabolic Disorders, 2020: 1-8.

ADAMSON P.D., NEWBY D.E., HILL C.L., COLES A., DOUGLAS P.S., and FORDYCE C.B. Comparison of international guidelines for assessment of suspected stable angina: insights from the PROMISE and SCOT-HEART. JACC: Cardiovascular Imaging, 2018, 11(9): 1301-10.

HAEMMIG S., SIMION V., YANG D., DENG Y., and FEINBERG M.W. Long non-coding RNAs in cardiovascular pathology, diagnosis, and therapy. Current Opinion in Cardiology, 2017, 32(6): 776.

VAUSORT M., WAGNER D.R., and DEVAUX Y. Long non-coding RNAs in patients with acute myocardial infarction. Circulation research, 2014, 115(7): 668-77.

ZHANG M., GU H., XU W., and ZHOU X. Down-regulation of lncRNA MALAT1 reduces cardiomyocyte apoptosis and improves left ventricular function in diabetic rats. International Journal of Cardiology, 2016, 203: 214-216.

YAN C., CHEN J., and CHEN N. Long non-coding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability. Scientific Reports, 2016, 6(1): 1-11.

SOHRABIFAR N., GHADERIAN S.M.H., ALIPOUR P.S., GHAEDI H., and JAFARI H. Variation in the expression level of MALAT1, MIAT and XIST lncRNAs in coronary artery disease patients with and without type 2 diabetes mellitus. Archives of Physiology and Biochemistry, 2020: 1-8.

ALFAIFI M, BEG M.M.A., ALSHAHRANI M.Y., AHMAD I., ALKHATHAMI A.G., JOSHI P.C., ALSHEHRI O.M., ALAMRI A.M., and VERMA A.K. Circulating long non-coding RNAs NKILA, NEAT1, MALAT1, and MIAT expression and their association in type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 2021, 9(1): e001821.

TORAIH E.A., EL-WAZIR A., ALGHAMDI S.A., ALHAZMI A.S., EL-WAZIR M., ABDEL-DAIM M.M., and FAWZY M.S. Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events. Genetics and Molecular Biology, 2019, 42: 509-18.


  • There are currently no refbacks.